Irene Acerbi Soto, PhD, PMP, holds a PhD in Biomedical Engineering from the Politecnico di Milano, with collaborative research experience spanning human lung cell biophysics at the Hospital Clínic de Barcelona and translational breast cancer research at the University of California, San Francisco.
Since 2016, she has led site research operations for the WISDOM Study, bringing deep expertise in clinical research operations, project management, and international collaboration. PMP-certified, Dr. Acerbi Soto is particularly passionate about working in multidisciplinary teams—bridging clinicians, engineers, and patient advocates to advance impactful oncology research.
Originally from North Carolina, my interest in clinical research started in college working as a research assistant for burn and transplant research and continued after graduation working at a Contract Research Organization. After moving to NYC, I wanted to move to the patient side of research and worked as a Radiation Oncology Clinical Research Coordinator at Montefiore Medical Center. After gaining experience and knowledge, I worked in Radiation Oncology at Memorial Sloan Kettering Cancer Center initially spearheading our newly created Quality Assurance program, and then moved into a supervisor role managing Clinical Research Coordinators. After relocating to the Bay Area, I shifted gears working in allergy research clinical operations with the Immune Tolerance Network. After realizing I missed the world of oncology and management, I found my current role as an Associate Director of Clinical Research Programs in the UCSF Cancer Center managing several programs.
Lucrecia Marquez-Rosado, M.D., Ph.D., is a physician-scientist with over 20 years of experience in oncology, immunology, and drug discovery in both academia and biotech. She completed her clinical training at the Salvador Zubirán National Institute, earned her Ph.D. in Cell Biology from CINVESTAV, and finished a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center. Before co-founding LuMiAL Bio, she held scientific roles at Boehringer Ingelheim, SIBTECH, and Nurix Therapeutics, where she led cross-functional teams involved in translational research programs.
Lucrecia expertise includes Novel Therapeutic Modalities, biomarkers and disease-positioning strategies, focuses on translating innovative science into clinically actionable oncology programs.
Ann Mongan is a Subject Matter Expert in translational research and biomarker development, with her most recent role being Executive Director of Translational Research at Bristol Myers Squibb. With nearly two decades of experience, she has worked on more than 10 drugs (including ibrutinib and mezigdomide), from IND through all phases of development. Her experience spans multiple therapeutic areas, including oncology, neuroscience, and autoimmune diseases, and includes work at both large companies (BMS, AbbVie, Amgen) and small companies (Annexon). She received a PhD in Bioinformatics from UC San Diego and is also an expert in AI/ML and the integration of generative AI applications into science.
